FARON Stock Overview
Operates as a clinical stage drug discovery and development company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Faron Pharmaceuticals Oy Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1.78 |
| 52 Week High | UK£4.48 |
| 52 Week Low | UK£1.05 |
| Beta | 0.33 |
| 11 Month Change | -29.21% |
| 3 Month Change | -13.19% |
| 1 Year Change | -42.36% |
| 33 Year Change | -54.02% |
| 5 Year Change | n/a |
| Change since IPO | -48.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| FARON | FI Biotechs | FI Market | |
|---|---|---|---|
| 7D | -3.6% | -6.9% | -1.7% |
| 1Y | -42.4% | 0.8% | -2.0% |
Return vs Industry: FARON underperformed the Finnish Biotechs industry which returned 0.8% over the past year.
Return vs Market: FARON underperformed the Finnish Market which returned -2% over the past year.
Price Volatility
| FARON volatility | |
|---|---|
| FARON Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in FI Market | 6.5% |
| 10% least volatile stocks in FI Market | 2.6% |
Stable Share Price: FARON's share price has been volatile over the past 3 months compared to the Finnish market.
Volatility Over Time: FARON's weekly volatility has decreased from 15% to 10% over the past year, but is still higher than 75% of Finnish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 34 | Juho Jalkanen | www.faron.com |
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company is also developing bexmarilimab, which is in phase 2 clinical trial for indications of solid tumors; and in phase 1 clinical trial for indications of acute myeloid leukemia and myelodysplastic syndromes.
Faron Pharmaceuticals Oy Fundamentals Summary
| FARON fundamental statistics | |
|---|---|
| Market cap | €187.78m |
| Earnings (TTM) | -€31.61m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.9x
P/E RatioIs FARON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FARON income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €31.61m |
| Earnings | -€31.61m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.30 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 897.6% |
How did FARON perform over the long term?
See historical performance and comparison